Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > ARCHIVE
ARCHIVE
- Bayer Aiming for Top-10 Spot in Global Ethical Drug Market by 2015
July 18, 2011
- JACDS, JPA to Cooperate Regarding nternet Drug Sales, Unification of Basic Dispensing Fees
July 18, 2011
- Sandoz, Nipro Team Up to Develop, Market Generics
July 18, 2011
- Integration of Nycomed to Accelerate Development of World-class Workforce: Takeda
July 18, 2011
- Korosho Calls For Study on Deregulation of Online OTC Drug Sales in FY2011
July 18, 2011
- Pharmacists Call For Elimination of “No Generics”Option on Prescription Forms: Survey
July 18, 2011
- Problems Can't Be Solved by Meeting Only Once a Year: Mr Matsutani
July 18, 2011
- Regulatory Strategy Consultation to Upgrade Quality of Review, Development: Mr Hirayama of Korosho
July 18, 2011
- Bristol-Myers, AZ Report Breast, Bladder Cancer Findings for Investigational Diabetes Drug
July 18, 2011
- Foreign-affiliated Drug Makers Hire More New Graduates in 2011
July 18, 2011
- Total Review Period for Standard Products Reduced by 4.5 Months to 14.7 Months: PMDA
July 18, 2011
- Positive PII Results for Takeda's TAK-875 Presented at ADA
July 18, 2011
- Ryukaikon Calls For Further Studies on Bar Code Labeling
July 18, 2011
- Application for Partial Changes Acceptable When Crystal Form Is Changed: Korosho
July 11, 2011
- Towa to Actively Develop Value Added Generics
July 11, 2011
- Korosho to Study Application of Cost-Benefit Assessment to Reimbursement Pricing
July 11, 2011
- Research-oriented Companies Provide Reliable Info. on Generics: Prof. Kobayashi
July 11, 2011
- PMDA to Bring Domestic GMP into Greater Harmony with PIC/S GMP
July 11, 2011
- Hospitals Lose Money by Using Herceptin for Stomach Cancer: Chuikyo's DPC Subcommittee
July 11, 2011
- Sanofi-aventis K.K. Aiming for Growth in “Upper Single Digits” Pres. Moulding
July 11, 2011
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…